Mr. Colin Chang joined Certara in September 2008. He has been involved in PK/PD analyses and reporting across Phases 1 and 2 of drug development for industry sponsors. His work includes using state-of-the-art noncompartmental as well as population PK/PD modeling and simulation methods in support of drug development programs.
He has broad experience in several therapeutic areas such as oncology, inflammatory and various rare diseases, and has been involved in programs using both small molecule and monoclonal antibody therapies. Prior to joining Certara, he earned an MSc from McGill University and a graduate diploma in drug development from Université de Montréal, and also worked at Sanofi in early-stage drug discovery.